<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360bbb–8" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360bbb–8/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360bbb–8/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360bbb_8"><akn:num>360bbb–8</akn:num><akn:heading>Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of tr</akn:heading><akn:content><akn:p>§ 360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments(a) In generalFor the purpose of promoting the efficiency of and informing the review by the Food and Drug Administration of new drugs and biological products for rare diseases and drugs and biological products that are genetically targeted, the following shall apply:(1) Consultation with stakeholdersConsistent with sections X.C and IX.E.4 of the PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 through 2017, as referenced in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012, the Secretary shall ensure that opportunities exist, at a time the Secretary determines appropriate, for consultations with stakeholders on the topics described in subsection (b).


(2) Consultation with external experts(A) In generalThe Secretary shall develop and maintain a list of external experts who, because of their special expertise, are qualified to provide advice on rare disease issues, including topics described in subsection (b). The Secretary may, when appropriate to address a specific regulatory question, consult such external experts on issues related to the review of new drugs and biological products for rare diseases and drugs and biological products that are genetically targeted, including the topics described in subsection (b), when such consultation is necessary because the Secretary lacks the specific scientific, medical, or technical expertise necessary for the performance of the Secretary’s regulatory responsibilities and the necessary expertise can be provided by the external experts.


(B) External expertsFor purposes of subparagraph (A), external experts are individuals who possess scientific or medical training that the Secretary lacks with respect to one or more rare diseases.




(b) Topics for consultationTopics for consultation pursuant to this section may include—(1) rare diseases;</akn:p></akn:content><akn:subsection eId="subsec_360bbb_8_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general For the purpose of promoting the efficiency of and informing the review by the Food and Drug Administration of new drugs and biological products for rare diseases and drugs and biological products that are genetically targeted, the following shall apply:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_8_b"><akn:num>(b)</akn:num><akn:heading>Topics for consultation</akn:heading><akn:content><akn:p>(b) Topics for consultation Topics for consultation pursuant to this section may include—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_8_c"><akn:num>(c)</akn:num><akn:heading>Classification as special government employees</akn:heading><akn:content><akn:p>(c) Classification as special government employees The external experts who are consulted under this section may be considered special government employees, as defined under section 202 of title 18.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_8_d"><akn:num>(d)</akn:num><akn:heading>Protection of confidential information and trade secrets</akn:heading><akn:content><akn:p>(d) Protection of confidential information and trade secrets</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_8_e"><akn:num>(e)</akn:num><akn:heading>Other consultation</akn:heading><akn:content><akn:p>(e) Other consultation Nothing in this section shall be construed to limit the ability of the Secretary to consult with individuals and organizations as authorized prior to July 9, 2012.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_8_f"><akn:num>(f)</akn:num><akn:heading>No right or obligation</akn:heading><akn:content><akn:p>(f) No right or obligation</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_8_g"><akn:num>(g)</akn:num><akn:heading>No delay in product review</akn:heading><akn:content><akn:p>(g) No delay in product review</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>